FDA approves Voraxaze from BTG for ultra-rare indication
This article was originally published in Scrip
The US FDA has granted approval for BTG's biologics license application for Voraxaze (glucarpidase) to treat high dose methotrexate toxicity, an ultra-rare indication with only 300 sufferers in the US per year.
You may also be interested in...
The sale of BTG Specialty Pharmaceuticals to two affiliates of European specialty firm SERB leaves Boston Scientific with BTG’s interventional oncology and vascular products.
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.